AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8229380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender nailing
Number of subjects: 113
Study 8229380 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 113
Study 3885103 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydiazyme enzyme immunoassay
Number of subjects: 514
Study 3885103 — intervention group
Group type: COMPARATOR
Intervention: Isolation of Chlamydia trachomatis in cycloheximide‐treated McCoy cells
Number of subjects: 514
Study 30219067 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls or text messages intervention
Number of subjects: 1155
Study 25616874 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours of leg compression after radiofrequency ablation
Number of subjects: 0
Study 25616874 — intervention group
Group type: COMPARATOR
Intervention: 72 hours of leg compression after radiofrequency ablation
Number of subjects: 0
Study 24240575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU daily of cholecalciferol combined with 100 mg of elemental calcium administered twice a day)
Number of subjects: 158
Study 24240575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg daily of elemental calcium administered twice a day)
Number of subjects: 158
Study 22687235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (care provided by the GP at the patient's own initiative)
Number of subjects: 180
Study 22687235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 180
Study 22687235 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular monitoring by a practice nurse
Number of subjects: 180
Study 22687235 — intervention group
Group type: EXPERIMENTAL
Intervention: All care modes (self-management, regular monitoring, usual care)
Number of subjects: 180
Study 18955545 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Number of subjects: 83
Study 18955545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 18955545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 18955545 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based intervention
Number of subjects: 83
Study 18302711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) with bortezomib
Number of subjects: 303
Study 18302711 — intervention group
Group type: COMPARATOR
Intervention: Total Therapy 2 (TT2)
Number of subjects: 303
Study 18302711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) in FGFR3 subgroup
Number of subjects: 303
Study 18302711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) matched with 300 patients by standard prognostic factors
Number of subjects: 303
Study 18302711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) for patients completing TT2 consolidation within 24 months
Number of subjects: 303
Study 16019881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative computer input devices (14 keyboards and pointing devices)
Number of subjects: 35
Study 16019881 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting existing workstation and customizing computer settings
Number of subjects: 35
Study 16019881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach of using alternative devices and customizing settings
Number of subjects: 35
Study 12462290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 300 mg once daily for 8 weeks
Number of subjects: 50
Study 12462290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10478810 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 30
Study 10478810 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (1 mg/kg)
Number of subjects: 30
Study 10478810 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug administered)
Number of subjects: 30
Study 10478810 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone and Amrinone
Number of subjects: 30
Study 9156883 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-fibroscopy and bronchoalveolar lavage (BAL)
Number of subjects: 60
Study 9156883 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring parameters: heart rate (HR), arterial blood pressure (ABP) and arterial O2 saturation (SaO2)
Number of subjects: 60
Study 9156883 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation during the investigation
Number of subjects: 60
Study 1878318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic startle probes (white noise bursts [50 ms; 95 dBA]) during extinction of aversively conditioned visual stimulus.
Number of subjects: 60
Study 1878318 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned startle reflex augmentation.
Number of subjects: 60
Study 1878318 — intervention group
Group type: EXPERIMENTAL
Intervention: Judged aversiveness to slides.
Number of subjects: 60
Study 6393868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 197
Study 6393868 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 197
Study 31976023 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Gastrectomy (PG)
Number of subjects: 2217
Study 31976023 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 2217
Study 28714376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or Apixaban
Number of subjects: 127
Study 28714376 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 127
Study 28714376 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 127
Study 26494411 — intervention group
Group type: COMPARATOR
Intervention: Once daily thoracic radiotherapy (TRT) of 42 Gy in 15 fractions (OD)
Number of subjects: 157
Study 26494411 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily thoracic radiotherapy (TRT) of 45 Gy in 30 fractions (BID)
Number of subjects: 157
Study 24907435 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0112 (0.04 to 3.6 mg, single intravitreal injection)
Number of subjects: 32
Study 24907435 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0112 (0.04-0.4 mg)
Number of subjects: 32
Study 24907435 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0112 (1.0 or 2.0 mg)
Number of subjects: 32
Study 24907435 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0112 (higher-dose cohorts)
Number of subjects: 32
Study 22294470 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin (75 mg twice daily for 2 days; 75 mg once on day 3)
Number of subjects: 100
Study 22294470 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (active control)
Number of subjects: 100
Study 22294470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study 20817247 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL 24% sucrose solution
Number of subjects: 59
Study 20817247 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL sterile water
Number of subjects: 59
Study 17588420 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 479
Study 17588420 — intervention group
Group type: COMPARATOR
Intervention: Noncoated sutures
Number of subjects: 479
Study 16240960 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct application of Clearfil AP‐X
Number of subjects: 20
Study 16240960 — intervention group
Group type: COMPARATOR
Intervention: Directly applied Filtek Z 250
Number of subjects: 20
Study 16240960 — intervention group
Group type: COMPARATOR
Intervention: Indirectly applied Clearfil AP‐X
Number of subjects: 20
Study 16240960 — intervention group
Group type: COMPARATOR
Intervention: Indirectly applied Filtek Z 250
Number of subjects: 20
Study 16240960 — intervention group
Group type: COMPARATOR
Intervention: Pulpal dentin
Number of subjects: 20
Study 16240960 — intervention group
Group type: COMPARATOR
Intervention: Remote dentin
Number of subjects: 20
Study 12000209 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 75 mg/day
Number of subjects: 16
Study 12000209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9527740 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24
Study 9527740 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 9527740 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (Control)
Number of subjects: 24
Study 9527740 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotension (all groups)
Number of subjects: 24
Study 7638640 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks
Number of subjects: 81
Study 7638640 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin 12 mg/m2 given as an intravenous infusion every 6 weeks
Number of subjects: 81
Study 7638640 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to paclitaxel therapy after progression on mitomycin
Number of subjects: 81
Study 2199599 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 500-mg clotrimazole vaginal tablets
Number of subjects: 55
Study 2199599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2199599 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida isolated at follow-up visit
Number of subjects: 55
Study 773082 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan)
Number of subjects: 29
Study 773082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31870139 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar monoclonal antibodies awareness
Number of subjects: 151
Study 31870139 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of cost saving
Number of subjects: 151
Study 31870139 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about immunogenicity
Number of subjects: 151
Study 31870139 — intervention group
Group type: EXPERIMENTAL
Intervention: Interchangeability perception
Number of subjects: 151
Study 31870139 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in using biosimilars
Number of subjects: 151
Study 28813414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral synbiotic preparation (Lactobacillus plantarum plus fructooligosaccharide)
Number of subjects: 4556
Study 28813414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4556
Study 25370591 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ warm-up programme
Number of subjects: 265
Study 25370591 — intervention group
Group type: COMPARATOR
Intervention: Regular training routine
Number of subjects: 265
Study 23510607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed letter
Number of subjects: 4115
Study 23510607 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 4115
Study 23510607 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4115
Study 21527122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (40 mg/d)
Number of subjects: 481
Study 21527122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 19056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran flakes containing 11 mg total ARs
Number of subjects: 16
Study 19056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran flakes containing 22 mg total ARs
Number of subjects: 16
Study 19056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran flakes containing 44 mg total ARs
Number of subjects: 16
Study 19056600 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 16
Study 17462119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol users
Number of subjects: 46
Study 17462119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 15657470 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meal (GI value of 77)
Number of subjects: 8
Study 15657470 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) meal (GI value of 37)
Number of subjects: 8
Study 15657470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HGI and LGI meals
Number of subjects: 8
Study 11527284 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment protocol including individual certified nursing assistants (CNAs), in-service training for CNAs, and memory notebooks.
Number of subjects: 0
Study 11527284 — intervention group
Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 0
Study 9815587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporine A (12.5 mg/kg/day for 5 days) with continuous-infusion vinblastine (1.2 mg/m2/day for 4 days or 1.5 mg/m2/day for 5 days)
Number of subjects: 63
Study 9815587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tamoxifen (400 mg/m2 loading dose and 300 mg/m2/day for 13 days) with continuous-infusion vinblastine
Number of subjects: 63
Study 9815587 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion vinblastine alone (1.2 mg/m2/day for 4 days or 1.5 mg/m2/day for 5 days)
Number of subjects: 63
Study 7962322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1241
Study 7962322 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 1241
Study 7962322 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 1241
Study 7962322 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 1241
Study 7962322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lipids
Number of subjects: 1241
Study 7962322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and crude fiber
Number of subjects: 1241
Study 3503318 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlocked car door condition
Number of subjects: 80
Study 3503318 — intervention group
Group type: COMPARATOR
Intervention: Locked car door condition
Number of subjects: 80
Study 29329061 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking exercise (40-59% of HRR) for 10, 20, 30, 45, or 60 minutes with recovery periods of 5, 15, or 30 minutes
Number of subjects: 352
Study 29329061 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity walking exercise (40-59% of HRR) for 60 minutes with 5 minutes recovery
Number of subjects: 352
Study 29329061 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity walking exercise (40-59% of HRR) for 10 minutes
Number of subjects: 352
Study 28499391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondrosphere® (low dose: 3-7 spheroids/cm², medium dose: 10-30 spheroids/cm², high dose: 40-70 spheroids/cm²)
Number of subjects: 75
Study 28499391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondrosphere® (all dose levels)
Number of subjects: 75
Study 25582116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 139
Study 25582116 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 139
Study 25582116 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 139
Study 25582116 — intervention group
Group type: COMPARATOR
Intervention: SAD participants
Number of subjects: 139
Study 25582116 — intervention group
Group type: EXPERIMENTAL
Intervention: All strategies
Number of subjects: 139
Study 25582116 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological parameters
Number of subjects: 139
Study 23592708 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 2706
Study 23592708 — intervention group
Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 2706
Study 19926194 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome guidance during CPR
Number of subjects: 68
Study 19926194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronome) during CPR
Number of subjects: 68
Study 19926194 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome guidance during CPR with bag/endotracheal tube
Number of subjects: 68
Study 19926194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronome) during CPR with bag/endotracheal tube
Number of subjects: 68
Study 19926194 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome guidance with secured airway
Number of subjects: 68
Study 19006745 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-moon supracapsular technique
Number of subjects: 100
Study 19006745 — intervention group
Group type: COMPARATOR
Intervention: Stop-and-chop technique
Number of subjects: 100
Study 16652321 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART
Number of subjects: 82
Study 16652321 — intervention group
Group type: COMPARATOR
Intervention: IDU-methadone (Control)
Number of subjects: 82
Study 16652321 — intervention group
Group type: COMPARATOR
Intervention: IDU-nonmethadone (Control)
Number of subjects: 82
Study 16652321 — intervention group
Group type: COMPARATOR
Intervention: non-IDU (Control)
Number of subjects: 82
Study 12791811 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET with intravenous injection of 120 MBq (18)F‐FDG
Number of subjects: 11
Study 12791811 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET
Number of subjects: 11
Study 11004058 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (bolus 2 mg/kg, then infusion 3 mg/kg/h)
Number of subjects: 24
Study 11004058 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 8972022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (30 anti-Xa IU/kg)
Number of subjects: 0
Study 8972022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (60 anti-Xa IU/kg)
Number of subjects: 0
Study 8972022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 anti-Xa IU/kg)
Number of subjects: 0
Study 8972022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 0
Study 1319311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole, 200 mg twice daily
Number of subjects: 32
Study 1319311 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amphotericin B, 0.6 mg/kg/day (or 0.3 mg/kg/day plus flucytosine, 150 mg/kg/day for some Candida infections)
Number of subjects: 32
Study 6230612 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen-sodium (825 mg)
Number of subjects: 124
Study 6230612 — intervention group
Group type: COMPARATOR
Intervention: paracetamol (1,000 mg)
Number of subjects: 124
Study 31752981 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with temozolomide (TMZ)
Number of subjects: 250
Study 31752981 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 250
Study 29378658 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment for performance (P4P)
Number of subjects: 3000
Study 26925771 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in Evidence-Based Medicine (EBM) for 6 months
Number of subjects: 45
Study 25066654 — intervention group
Group type: EXPERIMENTAL
Intervention: nutritional counseling + symbiotic
Number of subjects: 18
Study 25066654 — intervention group
Group type: COMPARATOR
Intervention: nutritional counseling + placebo
Number of subjects: 18
Study 22859907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rap System of Stress Stimulation (RSSS)
Number of subjects: 92
Study 22859907 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 18853138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids (5 micromol/l)
Number of subjects: 23
Study 18853138 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous surfactant (poractant-alfa)
Number of subjects: 23
Study 18853138 — intervention group
Group type: COMPARATOR
Intervention: Bile acids (lower concentrations)
Number of subjects: 23
Study 17599855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 22
Study 17599855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralente insulin
Number of subjects: 22
Study 17599855 — intervention group
Group type: COMPARATOR
Intervention: Comparison of glargine and Ultralente
Number of subjects: 22
Study 16035063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HCIG (75 mg/kg)
Number of subjects: 18
Study 16035063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HCIG (200 mg/kg)
Number of subjects: 18
Study 16035063 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 12350438 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (mean age=21.4+/‐2.5 years)
Number of subjects: 34
Study 12350438 — intervention group
Group type: COMPARATOR
Intervention: Older adults (mean age=75.5+/‐6.3 years)
Number of subjects: 34
Study 10417490 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal alone (25 g in 200 ml water)
Number of subjects: 9
Study 10417490 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal combined with gastric lavage (25 g charcoal after lavage)
Number of subjects: 9
Study 10417490 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml water)
Number of subjects: 9
Study 7766171 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltooligosaccharides mixture (IMO)
Number of subjects: 6
Study 7766171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenated derivative of isomaltooligosaccharides (IMO‐H)
Number of subjects: 6
Study 2187496 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased contact efforts for breast cancer screening
Number of subjects: 0
Study 2187496 — intervention group
Group type: COMPARATOR
Intervention: Minimum contact efforts for breast cancer screening
Number of subjects: 0
Study 2187496 — intervention group
Group type: COMPARATOR
Intervention: Reluctant participants
Number of subjects: 0
Study 7001668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite-free bedding
Number of subjects: 21
Study 7001668 — intervention group
Group type: COMPARATOR
Intervention: Ordinary bedding
Number of subjects: 21
Study 29190398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette with warning 'Smoking kills'
Number of subjects: 997
Study 29190398 — intervention group
Group type: EXPERIMENTAL
Intervention: Green cigarette
Number of subjects: 997
Study 29190398 — intervention group
Group type: COMPARATOR
Intervention: Standard cigarette
Number of subjects: 997